0000000000322240

AUTHOR

Fabbri A

showing 2 related works from this author

Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical hodgkin lymphoma and correlation with early FDG-PET a…

2017

In Hodgkin Lymphoma (HL), about 20% of patients still have relapsed/refractory disease and late toxic effects rate continue to rise with time. 'Early FDG-PET' and tissue macrophage infiltration (TAM) emerged as powerful prognostic predictors. The primary endpoint was to investigate the prognostic role of both early FDG-PET and TAM; the secondary endpoint was to test if early FDG-PET positivity could correlate with high TAM score. A cohort of 200 HL patients was analysed. Induction treatment plan consisted of two to six courses of ABVD and, if indicated, involved field radiation therapy. All patients repeated CT scan and FDG-PET after two cycles and after the completion of therapy. TAM in di…

AdultMaleAdolescentHodgkin’s lymphomaMacrophagePrognosiAntigens Differentiation MyelomonocyticVinblastineDisease-Free SurvivalCohort StudiesBleomycinYoung AdultAntigens CDFluorodeoxyglucose F18RecurrencePositron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsHumansCD68AgedAged 80 and overHodgkin's lymphomahematologyMacrophagesCD68; Hodgkin's lymphoma; macrophages; PET; prognosis; hematology; oncology; cancer researchAntibodies MonoclonalMiddle AgedPrognosisHodgkin DiseaseImmunohistochemistryDacarbazineTreatment OutcomePETDoxorubicinPositron-Emission Tomographyoncologycancer researchFemaleNeoplasm Recurrence LocalFollow-Up Studies
researchProduct

Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: The PAUSE study

2014

Abstract Background Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). Its safety was established in a thorough clinical development program. Objective To characterize the safety profile of dapoxetine in PE treatment and to report the incidence, severity, and type of adverse events. Design, setting, and participants We conducted a 12-wk, open-label, observational study with a 4-wk, postobservational contact. A total of 10 028 patients were enrolled, with 6712 patients (67.6%) treated with dapoxetine 30–60mg (group A)and 3316 (32.4%) treated with alternative care/nondapoxetine (group B). …

AdultComplementary TherapiesMalemedicine.medical_specialtyBenzylaminesAdolescentNauseaUrologyNaphthalenesDapoxetine Safety Cardiovascular events SyncopeSyncopeCardiovascular eventsYoung AdultInternal medicinePremature ejaculationmedicine80 and overCardiovascular events; Dapoxetine; Safety; Syncope; Adolescent; Adult; Aged; Aged 80 and over; Benzylamines; Complementary Therapies; Humans; Male; Middle Aged; Naphthalenes; Premature Ejaculation; Prospective Studies; Serotonin Uptake Inhibitors; Young AdultHumansProspective StudiesPremature EjaculationAdverse effectProspective cohort studyCardiovascular events; Safety; DapoxetineAgedCardiovascular events; Dapoxetine; Safety; Syncope; UrologyAged 80 and overSertralinebusiness.industrySettore MED/24 - UROLOGIAIncidence (epidemiology)Cardiovascular events; Dapoxetine; Safety; Syncope; Adolescent; Adult; Aged; Aged 80 and over; Benzylamines; Complementary Therapies; Humans; Male; Middle Aged; Naphthalenes; Premature Ejaculation; Prospective Studies; Serotonin Uptake Inhibitors; Young Adult; UrologyMiddle AgedDapoxetineCardiovascular events; Dapoxetine; syncope; SafetyDapoxetineAnesthesiaSerotonin Uptake InhibitorsObservational studymedicine.symptomSafetybusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugCardiovascular events Dapoxetine Safety Syncope
researchProduct